Wuhan Binhui Biotechnology

Binhui Biotech is a clinical-stage biopharmaceutical company headquartered in Wuhan, China, specializing in the development of next-generation oncolytic virus therapies for cancer treatment. The company leverages its proprietary oHSV2.0 platform, which utilizes a modified Herpes Simplex Virus type 2 (HSV-2) backbone to selectively target and destroy tumor cells while stimulating a systemic immune response. Its lead candidate, OH2, is an oncolytic virus expressing GM-CSF that is currently in Phase 2 clinical trials for various solid tumors, including melanoma and liver cancer. Beyond its core oncolytic virus programs, Binhui is expanding its portfolio to include recombinant proteins and therapeutic vaccines. The company operates its own GMP-compliant manufacturing facilities to support its clinical pipeline and future commercialization efforts.